USANA Health Sciences, Inc. has announced a significant amendment to its credit agreement, aimed at enhancing its financial flexibility. This move allows the company to increase its revolving credit facility to $75 million, with the potential to expand it further up to $200 million. The changes come as USANA seeks to strengthen its position in the medicinal chemicals and botanical products sector.

The amendment, which was filed with the Securities and Exchange Commission on October 5, 2026, reflects USANA's proactive approach to managing its financial obligations and capitalizing on growth opportunities. The company now must maintain a minimum consolidated EBITDA of $100 million for each trailing four-fiscal-quarter period, a requirement that adjusts if its revolving exposure is below $50 million.

Background

USANA Health Sciences, Inc. operates in the medicinal chemicals and botanical products sector, classified under SIC code 2833. The company is publicly traded on the New York Stock Exchange under the ticker symbol USNA. USANA focuses on manufacturing high-quality nutritional products and dietary supplements, catering to a global market. Recent filings indicate a commitment to transparency and regulatory compliance, with a history of timely disclosures.

What the Filing Says

According to the filing, the amendment to the credit agreement was executed on September 30, 2026. It includes provisions for:

  • A minimum consolidated EBITDA covenant of $100 million, adjustable to $70 million under specific conditions.
  • Increased limits on the aggregate book value of property that can be sold by the company and its subsidiaries, rising from $500,000 to $2.5 million.
  • New permissions for USANA Australia Pty, Ltd to sell real property in Sydney, Australia, allowing for greater flexibility in asset management.
  • Clarifications regarding sale and leaseback transactions, which remain largely prohibited unless agreed upon by the required lenders.

Impact

This amendment may have far-reaching implications for USANA and its stakeholders. The increased credit facility provides the company with more options for financing its operations and pursuing growth initiatives. The new financial covenants will require careful management of earnings and assets, potentially impacting strategic decisions. Competitors in the medicinal chemicals and botanical products industry will likely monitor USANA's financial health and operational adjustments closely.

What's Next

The filing does not specify what happens next. However, USANA's management will need to comply with the new financial covenants and may consider further strategic moves to leverage its enhanced credit capacity.

Source: SEC Filing Accession Number 0000896264-26-000060